sr 48692 has been researched along with epidermal growth factor in 1 studies
| Studies (sr 48692) | Trials (sr 48692) | Recent Studies (post-2010) (sr 48692) | Studies (epidermal growth factor) | Trials (epidermal growth factor) | Recent Studies (post-2010) (epidermal growth factor) |
|---|---|---|---|---|---|
| 203 | 3 | 36 | 24,155 | 217 | 4,699 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amorino, GP; Casarez, EV; Dasilva, JO; Dunlap-Brown, ME; Dziegielewski, J; Parsons, SJ; Valerie, NC | 1 |
1 other study(ies) available for sr 48692 and epidermal growth factor
| Article | Year |
|---|---|
Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation.
Topics: Adenocarcinoma; Androgens; Animals; Apoptosis; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phosphorylation; Prostatic Neoplasms; Protein Processing, Post-Translational; Pyrazoles; Quinolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptors, Androgen; Receptors, Neurotensin; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2011 |